Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coronary Perfusion Pressure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Coronary Perfusion Pressure. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-002261-36 Sponsor Protocol Number: CardioPET™P-02 Start Date*: 2012-11-08
    Sponsor Name:FluoroPharma Medical
    Full Title: A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects with Coronary Artery Disease
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002055-28 Sponsor Protocol Number: SK-DMDPA-02 Start Date*: 2017-10-13
    Sponsor Name:Synektik Spółka Akcyjna
    Full Title: Safety and dose optimization for [11C] DMDPA as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected coronary artery disease (CAD).
    Medical condition: known or suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002615-25 Sponsor Protocol Number: GE-262-001 Start Date*: 2020-03-27
    Sponsor Name:GE Healthcare Ltd.
    Full Title: An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients
    Medical condition: Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacolo...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10028603 Myocardial perfusion scan LLT
    20.0 100000004848 10065141 Vascular diagnostic procedure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001584-77 Sponsor Protocol Number: MEIN/10/Ran-PCI/005 Start Date*: 2012-10-08
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: Effect of Ranolazine in ischemic patients with indication of staged interventional therapy
    Medical condition: Stable Angina Pectoris
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10049194 Stable angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000629-38 Sponsor Protocol Number: ACT14656 Start Date*: 2017-07-20
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients with Microvascular Angina (MVA) and/or Persistent Stable Angina despi...
    Medical condition: Microvascular coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10072685 Microvascular coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004082-25 Sponsor Protocol Number: D5130C00137 Start Date*: 2015-03-27
    Sponsor Name:Hellenic Cardiovascular Research Society
    Full Title: A multicenter, prospective, randomized, open label, blinded endpoint, active-comparator trial to assess the MIcrovascular integrity and left ventricular function Recovery after clopidogrel or Ticag...
    Medical condition: Patients with Myocardial Infarction with ST-segment elevation (STEMI) undergoing thrombolysis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003614-27 Sponsor Protocol Number: GIA-DAP-16-005 Start Date*: 2017-08-16
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart)
    Medical condition: TYPE 2 DIABETES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002942-20 Sponsor Protocol Number: EFC5826 Start Date*: 2005-12-29
    Sponsor Name:sanofi-aventis recherche et developpement
    Full Title: Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obe...
    Medical condition: Patients with abdominal obesity at increased risk for cardiovascular events (myocardial infarctio, stroke and cardiovascular death)
    Disease: Version SOC Term Classification Code Term Level
    10.1 10051615 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prohibited by CA) GB (Prematurely Ended) ES (Completed) DE (Completed) AT (Prematurely Ended) FI (Completed) BE (Completed) DK (Suspended by CA) HU (Completed) CZ (Suspended by CA) IE (Prematurely Ended) PT (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001743-31 Sponsor Protocol Number: NL43882.029.13 Start Date*: 2013-08-06
    Sponsor Name:VU University Medical Center
    Full Title: The cardiovascular effects of hyperoxia during and shortly after CABG surgery
    Medical condition: During and after coronary artery bypass graft operation we will investigate the cardiovascular effects of hyperoxia on blood pressure, cardiac function, microcirculation and ischemia/reperfusion.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005618-32 Sponsor Protocol Number: 2021-HJEPharma-002 Start Date*: 2022-06-29
    Sponsor Name:Rigshospitalet
    Full Title: Dexamethasone, olanzapine, flow-targeted versus pressure-targeted hemodynamic management, and low tidal volume ventilation in patients undergoing on-pump cardiac surgery – a multifactorial design r...
    Medical condition: We investigate the efficacy of two pharmaceutical interventions for reducing mortality and organ damage, and shortening length of hospital stay in patients undergoing heart surgery (i.e. coronary a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10008937 Chronic ischemic heart disease, unspecified LLT
    21.1 10042613 - Surgical and medical procedures 10061994 Heart valve operation PT
    20.0 10007541 - Cardiac disorders 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001250-91 Sponsor Protocol Number: GV-002.001 Start Date*: 2005-10-04
    Sponsor Name:GenVec, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in "No Option" Patients with Cla...
    Medical condition: Moderate to severe angina pectoris due to advanced coronary artery disease (CAD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) DE (Completed) GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017831-16 Sponsor Protocol Number: 26169 Start Date*: 2010-07-15
    Sponsor Name:Institute of pharmacology, Aarhus university
    Full Title: Effects of 6 months intensive vasodilating treatment on vascular resistance and coronary flow reserve in hypertensive patients
    Medical condition: Essential Hypertension and changes in the vasculature related to high blood pressure.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    12.1 10015489 Essential hypertension, benign LLT
    12.1 10015491 Essential hypertension, unspecified LLT
    12.1 10020772 Hypertension LLT
    12.1 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001883-31 Sponsor Protocol Number: CARMRUSMIAMBULANCE20190823 Start Date*: 2020-02-25
    Sponsor Name:VU Univesity Medical Center (VUmc)
    Full Title: Microvascular Recovery using contrast Ultrasound in ST-elevation Myocardial Infarction in the ambulance (MRUSMI-Ambulance)
    Medical condition: ST elevation myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000500-26 Sponsor Protocol Number: 01-1-101 Start Date*: Information not available in EudraCT
    Sponsor Name:Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd)
    Full Title: An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases
    Medical condition: Regadenoson will be used as a pharmacologic stress agent in paediatric patients with cardiovascular problems, undergoing a clinically indicated myocardial perfusion MRI
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10065141 Vascular diagnostic procedure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-004976-35 Sponsor Protocol Number: CVT 5131 Start Date*: 2005-04-01
    Sponsor Name:CV Therapeutics, Inc.
    Full Title: A Phase III, Randomized, Double-Blind Study of Intravenous CVT 3146 vs. Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging
    Medical condition: Myocardial Ischaemia (diagnosis of )
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001802-30 Sponsor Protocol Number: TMP-3001-2020-30 Start Date*: 2021-10-28
    Sponsor Name:Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)
    Full Title: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma)
    Medical condition: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004402-42 Sponsor Protocol Number: HCMRanIT001 Start Date*: 2016-10-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A pilot study assessing the effects of Ranolazine on coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10020204 HOCM Hypertrophic obstructive cardiomyopathy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020203 HOCM LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA